Reuss J - Search Results

1

Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC.

Nassar AH, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung JM, Lin JJ, Liu Y, Lin SH, Parikh K, Sridhar A, Shakya P, Dilling TJ, Kaldas D, Gray JE, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron TU, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo JV, Neal JW, Wakelee HA, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski DJ, Naqash AR, Goldberg SB, Kim SY. Nassar AH, et al. Among authors: reuss j. J Thorac Oncol. 2025 Jan;20(1):109-118. doi: 10.1016/j.jtho.2024.09.1379. Epub 2024 Sep 10. J Thorac Oncol. 2025. PMID: 39260522

2

Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature.

Reuss JE, Kunk PR, Stowman AM, Gru AA, Slingluff CL Jr, Gaughan EM. Reuss JE, et al. J Immunother Cancer. 2016 Dec 20;4:94. doi: 10.1186/s40425-016-0199-9. eCollection 2016. J Immunother Cancer. 2016. PMID: 28031822 Free PMC article.

3

Subacute loss of vision in one eye · rash on hands and feet · plaques with scaling on genitals · Dx?

Nunn A, Sturek JM, Reuss JE, Rein MF, Heysell SK. Nunn A, et al. J Fam Pract. 2017 Dec;66(12):E9-E11. J Fam Pract. 2017. PMID: 29202152

4

Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond.

Reuss JE, Suresh K, Naidoo J. Reuss JE, et al. Curr Oncol Rep. 2020 May 16;22(6):56. doi: 10.1007/s11912-020-00920-z. Curr Oncol Rep. 2020. PMID: 32415399 Review.

5

Immunotherapy for mesothelioma: rationale and new approaches.

Reuss JE, Forde PM. Reuss JE, et al. Clin Adv Hematol Oncol. 2020 Sep;18(9):562-572. Clin Adv Hematol Oncol. 2020. PMID: 33006585 Review.

6

Naidoo J, Reuss JE, Suresh K, Feller-Kopman D, Forde PM, Mehta Steinke S, Rock C, Johnson DB, Nishino M, Brahmer JR. Naidoo J, et al. Among authors: reuss je. J Immunother Cancer. 2020 Jun;8(1):e000984. doi: 10.1136/jitc-2020-000984. J Immunother Cancer. 2020. PMID: 32554619 Free PMC article.

7

Use of on-therapy ctDNA monitoring in a patient with KIF5B-RET fusion positive advanced non-small cell lung cancer: a case report.

Yeung V, Kim C, Kiedrowski LA, Liu SV, Reuss JE. Yeung V, et al. Transl Lung Cancer Res. 2022 Jan;11(1):111-116. doi: 10.21037/tlcr-21-571. Transl Lung Cancer Res. 2022. PMID: 35242632 Free PMC article.

8

Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report.

Wilgucki M, Yeung V, Ho G, Bravo Montenegro GL, Jones G, Reuss JE, Liu SV, Kim C. Wilgucki M, et al. JTO Clin Res Rep. 2022 Aug 5;3(10):100396. doi: 10.1016/j.jtocrr.2022.100396. eCollection 2022 Oct. JTO Clin Res Rep. 2022. PMID: 36188633 Free PMC article.

9

Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic Class.

Marks JA, Wilgucki M, Liu SV, Reuss JE. Marks JA, et al. Curr Oncol Rep. 2022 Dec;24(12):1829-1841. doi: 10.1007/s11912-022-01334-9. Epub 2022 Oct 5. Curr Oncol Rep. 2022. PMID: 36197593 Review.

10

Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer.

Rosner S, Reuss JE, Zahurak M, Zhang J, Zeng Z, Taube J, Anagnostou V, Smith KN, Riemer J, Illei PB, Broderick SR, Jones DR, Topalian SL, Pardoll DM, Brahmer JR, Chaft JE, Forde PM. Rosner S, et al. Among authors: reuss je. Clin Cancer Res. 2023 Feb 16;29(4):705-710. doi: 10.1158/1078-0432.CCR-22-2994. Clin Cancer Res. 2023. PMID: 36794455 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

113 results

Search Page

Filters